Mathias Damkjær1, Kjell Håkansson1, Thomas Kallemose2, Charlotte Suppli Ulrik1,3, Nina Godtfredsen1,3. 1. Department of Respiratory Medicine, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark. 2. Clinical Research Centre, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark. 3. Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Abstract
BACKGROUND: Statins have, due to their anti-inflammatory properties, been suggested to potentially improve chronic obstructive pulmonary disease (COPD) outcomes. We aimed to investigate the effect of statins on time to first exacerbation and all-cause mortality in high-risk COPD outpatients. METHODS: All outpatients with COPD seen at the Department of Respiratory Medicine, Copenhagen University Hospital Amager and Hvidovre, Denmark in 2016 were identified and followed for 3.5 years in this retrospective, registry-based cohort study of time to first acute exacerbation of COPD (AECOPD) or death. AECOPD was defined as a rescue course of oral corticosteroid and/or hospital admission. The association was estimated using time-varying crude and multivariable Cox proportional hazard regression. RESULTS: The cohort comprised 950 COPD outpatients, mean (SD) age 71 (11) years, and FEV1 44% predicted (IQR 33%; 57%). The annual exacerbation rate was 0.88 (1.68) and 211 patients (22%) had a history of hospital admission for AECOPD in the 12 months prior to index date. Three hundred and ninety-three patients (41.4%) were defined as statin users, with 131 (33.3%) having filled the first prescription for statin after index date. Statin use was not associated with reduced risk of AECOPD. When stratifying for moderate and severe exacerbations in a sub-analysis in the same model, statin use did not have an increased HR for exacerbation of either severity (HR = 1.02 (95% CI 0.85to 1.24; p = 0.811) and HR = 1.07 (95% CI 0.89 to 1.29; p = 0.492) respectively). Statin use was not associated with all-cause mortality (HR 1.05 (95% CI, 0.75 to 1.47, p = 0.777)). CONCLUSION: We did not find any association between statin use and risk of AECOPD or all-cause mortality. The result adds to the evidence that an aggressive approach with statin treatment upfront is not beneficial in COPD, unless prescribed according to current guidelines for cardiovascular diseases.
BACKGROUND: Statins have, due to their anti-inflammatory properties, been suggested to potentially improve chronic obstructive pulmonary disease (COPD) outcomes. We aimed to investigate the effect of statins on time to first exacerbation and all-cause mortality in high-risk COPD outpatients. METHODS: All outpatients with COPD seen at the Department of Respiratory Medicine, Copenhagen University Hospital Amager and Hvidovre, Denmark in 2016 were identified and followed for 3.5 years in this retrospective, registry-based cohort study of time to first acute exacerbation of COPD (AECOPD) or death. AECOPD was defined as a rescue course of oral corticosteroid and/or hospital admission. The association was estimated using time-varying crude and multivariable Cox proportional hazard regression. RESULTS: The cohort comprised 950 COPD outpatients, mean (SD) age 71 (11) years, and FEV1 44% predicted (IQR 33%; 57%). The annual exacerbation rate was 0.88 (1.68) and 211 patients (22%) had a history of hospital admission for AECOPD in the 12 months prior to index date. Three hundred and ninety-three patients (41.4%) were defined as statin users, with 131 (33.3%) having filled the first prescription for statin after index date. Statin use was not associated with reduced risk of AECOPD. When stratifying for moderate and severe exacerbations in a sub-analysis in the same model, statin use did not have an increased HR for exacerbation of either severity (HR = 1.02 (95% CI 0.85to 1.24; p = 0.811) and HR = 1.07 (95% CI 0.89 to 1.29; p = 0.492) respectively). Statin use was not associated with all-cause mortality (HR 1.05 (95% CI, 0.75 to 1.47, p = 0.777)). CONCLUSION: We did not find any association between statin use and risk of AECOPD or all-cause mortality. The result adds to the evidence that an aggressive approach with statin treatment upfront is not beneficial in COPD, unless prescribed according to current guidelines for cardiovascular diseases.
Authors: Truls S Ingebrigtsen; Jacob L Marott; Peter Lange; Jesper Hallas; Børge G Nordestgaard; Jørgen Vestbo Journal: Respir Med Date: 2015-10-31 Impact factor: 3.415
Authors: Lisette I Z Kunz; Nick H Ten Hacken; Thérèse S Lapperre; Wim Timens; Huib A M Kerstjens; Annemarie van Schadewijk; Judith M Vonk; Jacob K Sont; Jiska B Snoeck-Stroband; Dirkje S Postma; Peter J Sterk; Pieter S Hiemstra Journal: Eur Respir J Date: 2017-06-15 Impact factor: 16.671
Authors: Gerard J Criner; John E Connett; Shawn D Aaron; Richard K Albert; William C Bailey; Richard Casaburi; J Allen D Cooper; Jeffrey L Curtis; Mark T Dransfield; MeiLan K Han; Barry Make; Nathaniel Marchetti; Fernando J Martinez; Dennis E Niewoehner; Paul D Scanlon; Frank C Sciurba; Steven M Scharf; Don D Sin; Helen Voelker; George R Washko; Prescott G Woodruff; Stephen C Lazarus Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Emanuel Citgez; Job van der Palen; Kirsten Koehorst-Ter Huurne; Kris Movig; Paul van der Valk; Marjolein Brusse-Keizer Journal: BMJ Open Respir Res Date: 2016-06-17